Skip to main content
ROVI Subsidiaries
Spain
Germany
France
Italy
Poland
Portugal
United Kingdom
Language
Spanish
Spanish
English
English
English
Español
Home
ROVI
History
Group structure
Business units
International expansion
Strategy
Licenses
Contact
Products
Prescription Pharmaceuticals
Hospital Products
Manufacturing
CDMO
Own product Manufacturing
R&D
Shareholders and Investors
The share
Investor's Calendar
News
Financial and Business Information
CMNV Communications
ESG
Corporate Governance
Telematic assistance access
Prior Registration On-Line Attendance
On-Line Attendance
Sustainability
Responsible governance
Commitment to people
Environmental Commitment
Ethics Channel
Media
FAQS
News
ROVI up to date
Contact
Work with Us
TELEMATIC ASSISTANCE ACCESS
Home
News
Results of the final analysis of the ABEL Phase II clinical trial
Wed, 19/10/2011 - 09:13
0 min
Download related document
Select rating
Give Results of the final analysis of the ABEL Phase II clinical trial 1/5
Give Results of the final analysis of the ABEL Phase II clinical trial 2/5
Give Results of the final analysis of the ABEL Phase II clinical trial 3/5
Give Results of the final analysis of the ABEL Phase II clinical trial 4/5
Give Results of the final analysis of the ABEL Phase II clinical trial 5/5
No votes yet
Related
ROVI holds its 2021 General Shareholders Meeting
Laboratorios Farmaceuticos Rovi, SA has held its today General Ordinary Shareholders Meeting, in which a valuation of the 2020 financial...
6 min
17/06/2021
The President of the Spanish government, Pedro Sánchez, makes an institutional...
During their visit to the facilities, they have been accompanied by the CEO of ROVI, Juan López-Belmonte; the vice president and CFO,...
2 min
14/05/2021
First quarter 2021 results presentation
0 min
13/05/2021
See More
Email
Facebook
Twitter
LinkedIn